Biotron Share Price Volatile as Investors Digest Latest Release
It’s been a rollercoaster ride for the Biotron Limited [ASX:BIT] share price, with the stock up 14.82% today, trading at $.155 at time of writing.
Reasons for the current volatility are hard to pin down, but profit-taking and new data released by the company could be factors.
The Biotron share price is down from a high of $.445 on 17 October, 2018:
Source: marketindex.com.au
Investors digesting new data from Biotron
For those of you with a biochemistry degree, the data can be found below:
Source: biotron.com.au
Source: biotron.com.au
Some highlights from the data include, a higher incidence of some side effects against placebo. These include headache, pyrexia (elevated body temperature), rash and rhinorrhoea (runny nose).
Additional quotes from the data include:
‘The BIT225 cohort had a significantly greater reduction of macrophage activation marker sCD163, a good indicator of all cause morbidity and mortality in HIV-2 patients. Additional reduction of this marker in patients taking BIT225 demonstrates significant immunological benefit.’
And:
‘The stimulation of the immune system in the BIT225 cohort makes this treatment approach a unique and potentially clinical beneficial step towards HIV-1 eradication.’
Statistically significant results
As for the data itself, there were a number of statistically significant decreases for biomarker sCD163, statistically significant CD8* response, and statistically significant sustained delay in decline of CD4*.
To conclude, it is worth stressing that this is a Phase 2 trial, and the researchers are still trying to understand their own medicine.
Investors will be hoping ongoing investigations prove positive.
Regards,
Lachlann Tierney,
For Money Morning
PS: Learn how to pick the best bio-tech stocks with our free report. The download is available right here.
Related Articles
Biotron Share Price Shoots 26% Higher on Preliminary COVID-19 Results
The hunt for a COVID-19 vaccine is ramping up. We learnt yesterday that the government has spent $1.7 billion on potential treatments. Hedging their bets on some $84 million worth of doses that will be ready for free rollouts by 2021…
Three Stocks to Watch during the Coronavirus Rollercoaster
Market volatility is continuing to rise amidst the ongoing global pandemic. Worst yet, it is difficult to pinpoint when this is likely to end. Markets are up one day and crashing down the next. It is a telling sign when investors begin to look for safety among some of Australia’s most speculative small-caps…
A Look at the Orthocell Share Price: Can It Keep Going Up?
Despite a recent pullback, it has been an exciting ride for investors with the Orthocell share price going through the roof on 8 May .Today we will be looking at what caused Orthocell’s remarkable rise and its prospects going forward.
Biotron Share Price Up, Letter to Shareholders Includes Useful Information
Early this morning, the share price of Biotron Limited [ASX:BIT] managed to spike up 7.69%, trading at 14 cents per share. In a letter to the shareholders, the company disclosed a couple of useful pieces of information.
Biotron Share Price Up as it Responds to ASX Query
The share price of Biotron is up 9.5% and trading at $0.115, at time of writing. It has been an exciting time for Biotron shareholders who, last month, could have sold their shares for a whopping $0.445.
Huge Gains for Biotron Share Price After Promising HIV Drug Trial Results
In just the past three trading days Biotron Limited [ASX:BIT] has rocketed up. As at time of writing, it’s trading at $.093, a 489% increase from three trading days ago where it closed at $.019. Biotron is a biotechnology research company working on a range of antiretroviral drugs. Antiretroviral drugs fight viruses, and Biotron has … Read More